Viridian Therapeutics (VRDN) Projected to Post Quarterly Earnings on Thursday

Viridian Therapeutics (NASDAQ:VRDN) is anticipated to announce its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.88) per share for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, February 27, 2026 at 4:00 PM ET.

Viridian Therapeutics Trading Down 0.6%

Shares of NASDAQ:VRDN opened at $28.11 on Thursday. The stock’s 50-day simple moving average is $31.55 and its two-hundred day simple moving average is $25.89. The stock has a market capitalization of $2.68 billion, a price-to-earnings ratio of -9.31 and a beta of 0.98. Viridian Therapeutics has a 52-week low of $9.90 and a 52-week high of $34.29. The company has a debt-to-equity ratio of 0.07, a quick ratio of 11.28 and a current ratio of 11.28.

Analysts Set New Price Targets

Several analysts recently issued reports on VRDN shares. Evercore restated an “outperform” rating and set a $44.00 target price on shares of Viridian Therapeutics in a research report on Tuesday, January 20th. Needham & Company LLC reissued a “buy” rating and set a $42.00 price objective on shares of Viridian Therapeutics in a research report on Wednesday, February 4th. Royal Bank Of Canada raised their target price on Viridian Therapeutics from $41.00 to $45.00 and gave the stock an “outperform” rating in a report on Thursday, November 6th. William Blair initiated coverage on Viridian Therapeutics in a report on Wednesday, December 3rd. They set an “outperform” rating for the company. Finally, UBS Group assumed coverage on Viridian Therapeutics in a research note on Wednesday, January 7th. They issued a “buy” rating and a $50.00 price objective on the stock. Thirteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $42.64.

Insider Activity at Viridian Therapeutics

In other news, insider Jennifer Tousignant sold 2,272 shares of the business’s stock in a transaction dated Wednesday, December 31st. The stock was sold at an average price of $31.16, for a total value of $70,795.52. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 1.58% of the stock is owned by insiders.

Institutional Trading of Viridian Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. XTX Topco Ltd purchased a new position in shares of Viridian Therapeutics during the fourth quarter valued at about $1,464,000. Virtus Investment Advisers LLC lifted its position in shares of Viridian Therapeutics by 13.4% in the fourth quarter. Virtus Investment Advisers LLC now owns 8,233 shares of the company’s stock worth $256,000 after buying an additional 971 shares in the last quarter. Wellington Management Group LLP boosted its stake in Viridian Therapeutics by 75.6% during the fourth quarter. Wellington Management Group LLP now owns 1,971,411 shares of the company’s stock valued at $61,350,000 after buying an additional 848,879 shares during the last quarter. Tudor Investment Corp ET AL purchased a new position in Viridian Therapeutics during the 4th quarter valued at approximately $1,606,000. Finally, Twinbeech Capital LP bought a new stake in Viridian Therapeutics in the 4th quarter worth approximately $1,484,000.

About Viridian Therapeutics

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.